Immunogenicity of hepatitis B vaccine among hemodialysis patients: Effect of revaccination of non-responders and duration of protection

Vaccine

Volumn 29, Issue 52, 2011, Pages 9618-9623

  Chaves, Sandra S ^a   Daniels, Danni ^a   Cooper, Brian W ^b,c   Malo Schlegel, Susan ^b   MacArthur, Susan ^d   Robbins, Karen C ^b   Kobetitsch, John F ^b   McDaniel, Aimee ^b   D'Avella, John F ^c   Alter, Miriam J ^e  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b HARTFORD HOSPITAL   (United States)

^c UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^d Divisions of Infectious Diseases Immunology and Excellence in Patient Safety and Clinical Quality   (United States)

^e UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

Duration of vaccine induced antibody; Hemodialysis patients; Hepatitis B vaccine; Hepatitis B virus; Immunogenicity

Indexed keywords

HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; RECOMBINANT HEPATITIS B VACCINE;

ADULT; ARTICLE; FEMALE; HEMODIALYSIS PATIENT; HEPATITIS B; HUMAN; IMMUNOGENICITY; MALE; PRIORITY JOURNAL; PROBABILITY; PROSPECTIVE STUDY; REVACCINATION; SURVIVAL RATE; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HUMANS; MALE; MIDDLE AGED; RENAL DIALYSIS; TIME FACTORS; VACCINATION;

EID: 82555168258     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.10.057     Document Type: Article

References (31)

1. CDC Recommendations of the Immunization Practices Advisory Committee (ACIP): inactivated hepatitis B virus vaccine. MMWR 1982, 31. 317-22, 327-8.
2. Miller E.R., Alter M.J., Tokars J.I. Protective effect of hepatitis B vaccine in chronic hemodialysis patients. Am J Kidney Dis 1999, 33:356-360.
3. Finelli L., Miller J.T., Tokars J.I., Alter M.J., Arduino M.J. National surveillance of dialysis-associated diseases in the United States, 2002. Semin Dial 2005, 18(January-February (1)):52-61.
4. Bond T.C., Patel P.R., Krisher J., Sauls L., Deane J., Strott K., et al. Association of standing-order policies with vaccination rates in dialysis clinics: a US-based cross-sectional study. Am J Kidney Dis 2009, 54(July (1)):86-94.
5. CDC Outbreaks of hepatitis B virus infection among hemodialysis patients, California, Nebraska, and Texas, 1994. MMWR 1996, 45:285-289.
6. Thompson N.D., Perz J.F., Moorman A.C., Holmberg S.D. Nonhospital health care-associated hepatitis B and C virus transmission: United States, 1998-2008. Ann Intern Med 2009, 150(January (1)):33-39. [Review].
7. Stevens C.E., Alter H.J., Taylor P.E., Zang E.A., Harley E.J., Szmuness W. Hepatitis B vaccine in patients receiving hemodialysis: immunogenicity and efficacy. N Engl J Med 1984, 311:496-501. and the Dialysis Vaccine Trial Study Group.
8. de Graeff P.A., Dankert J., de Zeeuw D., Gips C.H., van der Hem G.K. Immune response to two different hepatitis B vaccines in haemodialysis patients: a 2-year follow-up. Nephron 1985, 40:155-160.
9. Andre F.E. Summary of safety and efficacy data on a yeast-derived hepatitis B vaccine. Am J Med 1989, 87(Suppl. 3A):S14-S20. 125.
10. Zajac B.A., West D.J., McAleer W.J., Scolnick E.M. Overview of clinical studies with hepatitis B vaccine made by recombinant DNA. J Infect 1986, 13(Suppl. A):39-45.
11. Roll M., Norder H., Magnius L.O., Grillner L., Lindgren V. Nosocomial spread of hepatitis B virus (HBV) in a haemodialysis unit confirmed by HBV DNA sequencing. J Hosp Infect 1995, 30(May (1)):57-63.
12. Rault R., Freed B., Nespor S., Bender F. Efficacy of different hepatitis B vaccination strategies in patients receiving hemodialysis. ASAIO J 1995, 41(July-September (3)):M717-M719.
13. CDC Recommendations for preventing transmission of infections among chronic hemodialysis patients. MMWR Recomm Rep 2001, 50(April (RR-5)):1-43.
14. Hadler S.C., Judson F.N., O'Malley P.M., Altman N.L., Penley K., Buchbinder S., et al. Outcome of hepatitis B virus infection in homosexual men and its relation to prior human immunodeficiency virus infection. J Infect Dis 1991, 163(March (3)):454-459.
15. Goldwater P.N. Randomized, comparative trial of 20 vs. 40μg Engerix-B vaccine in hepatitis B vaccine nonresponders. Vaccine 1997, 15:353-356.
16. Fleiss J.L. Statistical methods for rates and proportions 1981, J. Wiley & Sons, p. 14.
17. Averhoff F., Mahoney F., Coleman P., Schatz G., Hurwitz E., Margolis H. Immunogenicity of hepatitis B vaccines: implications for persons at occupational risk of hepatitis B virus infection. Am J Prev Med 1998, 15:1-8.
18. Haubitz M., Ehlerding G., Beigel A., Heuer U., Hemmerling A.E., Thoma H.A. Clinical experience with a new recombinant hepatitis-B vaccine in previous non-responders with chronic renal insufficiency. Clin Nephrol 1996, 45:180-182.
19. Fabrizi F., Andrulli S., Bacchini G., Corti M., Locatelli F. Intradermal versus intramuscular hepatitis B re-vaccination in non-responsive chronic dialysis patients: a prospective randomized study with cost-effectiveness evaluation. Nephrol Dial Transplant 1997, 12:1204-1211.
20. CDC A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep 2006, 55(December (RR-16)):1-33.
21. Sezer S., Ozdemir F.N., Güz G., Arat Z., Colak T., Sengul S., et al. Factors influencing response to hepatitis B virus vaccination in hemodialysis patients. Transplant Proc 2000, 32(May (3)):607-608.
22. Taheri S., Shahidi S., Moghtaderi J., Seirafian S., Emami A., Eftekhari S.M. Response rate to hepatitis B vaccination in patients with chronic renal failure and end-stage renal disease: influence of Diabetes Mellitus. J Res Med Sci 2005, 10(December (6)):384-390.
23. Pin M., Compte M.T., Angelet P., Gállego C., Gutiérrez C., Martinez Vea A. Long-term evaluation of immune response to hepatitis B vaccine in 136 patients undergoing hemodialysis. Nefrologia 2009, 29(5):415-420. [Spanish].
24. Fabrizi F., Di Filippo S., Marcelli D., Guarnori I., Raffaele L., Crepaldi M., et al. Recombinant hepatitis B vaccine use in chronic hemodialysis patients. Long-term evaluation and cost-effectiveness analysis. Nephron 1996, 72(4):536-543.
25. Ramezani A., Eslamifar A., Banifazl M., Ahmadi F., Maziar S., Razeghi E., et al. Efficacy and long-term immunogenicity of hepatitis B vaccine in haemodialysis patients. Int J Clin Pract 2009, 63(March (3)):394-397.
26. Tsouchnikas I., Dounousi E., Xanthopoulou K., Papakonstantinou S., Thomoglou V., Tsakiris D. Loss of hepatitis B immunity in hemodialysis patients acquired either naturally or after vaccination. Clin Nephrol 2007, 68(October (4)):228-234.
27. Navarro J.F., Teruel J.L., Mateos M.L., Marcen R., Ortuno J. Antibody level after hepatitis B vaccination in hemodialysis patients: influence of hepatitis C virus infection. Am J Nephrol 1996, 16(2):95-97.
28. Buti M., Viladomiu L., Jardi R., Olmos A., Rodriguez J.A., Bartolome J., et al. Long-term immunogenicity and efficacy of hepatitis B vaccine in hemodialysis patients. Am J Nephrol 1992, 12(3):144-147.
29. Stevens C.E., Alter H.J., Taylor P.E., Zang E.A., Harley E.J., Szmuness W. Hepatitis B vaccine in patients receiving hemodialysis. Immunogenicity and efficacy. N Engl J Med 1984, 311(August (8)):496-501.
30. Peces R., de la Torre M., Alcazar R., Urra J.M. Prospective analysis of the factors influencing the antibody response to hepatitis B vaccine in hemodialysis patients. Am J Kidney Dis 1997, 29:239-245.
31. Pozzilli P., Arduini P., Visalli N., Sutherland J., Pezzella M., Galli C., et al. Reduced protection against hepatitis B virus following vaccination in patients with type 1 diabetes (insulin-dependent) diabetes. Diabetologia 1987, 30:817-819.